233: Manganese-porphyrin-catalyzed C-H fluorination: Hydrocarbons, but not drugs?

233: Manganese-porphyrin-catalyzed C-H fluorination: Hydrocarbons, but not drugs?

Monday, May 18, 2026 5:00 PM to 7:00 PM · 2 hr. (America/New_York)
White Room (Hershey Lodge)
Poster Presentation

Information

Abstract: Transformation of C-H to C-F bonds in organic compounds can be used in drug design to easily diversify molecular series under exploration. A particularly attractive fluorination reaction is the recently discovered aliphatic C-H bonds fluorination catalyzed by manganese(Mn)-containing porphyrins, which proceeds under mild conditions and with high yields. However, this fluorination technique has been applied so far only to a narrow range of carbon rich organic substrates. In this preliminary study, based on quantum chemical modeling of several key stages in the presumed mechanism of this reaction, we put forward a hypothesis to explain difficulties of extending the Mn-porphyrin-catalyzed fluorination to nitrogen rich drug-like molecules, namely, a significant growth of the height of the activation barrier for drug-like substrates. Specifically, we demonstrate that reaction energies are comparable for various substrates, including those for which Mn-porphyrin-catalyzed fluorination occurs and those for which it does not occur, and hence, thermodynamic factors are unlikely to control the observed differences in the reactivity. Next, we carry out a first-pass modeling of fluorination reaction paths for two substrates, cyclohexane versus piperidine, as a representative of the type of nitrogen rich compound that can and cannot be fluorinated under recommended conditions, and found a significant difference in activation energies (~7 kcal/mol vs ~40 kcal/mol), which might point at the reason for the difference in the reactivity. Further computational modeling is required to reveal the limitations of the Mn-porphyrin-catalyzed fluorination, and, if possible, possible ways to overcome such limitations.
Author/Institution List
V. Vennelakanti, Massachusetts Institute of Technology, Cambridge, Massachusetts, UNITED STATES|U. Reilly, A. Sinitsky, Pfizer, Cambridge, Massachusetts, UNITED STATES|

Log in

See all the content and easy-to-use features by logging in or registering!